Plastic Surgeons’ Perspective on the FDA Breast Implant Regulatory Mandates
Aesthetic Surgery Journal · 2024
DOI: 10.1093/asj/sjae106 ↗Kurz gefasst
Fachartikel in der Zeitschrift Aesthetic Surgery Journal, 2024. Verfasst von Karie Villanueva und 5 weiteren Autor:innen. Hauptthemen laut MEDLINE: United States Food and Drug Administration, Breast Implants, Breast Implantation, Surgeons. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
Background
In 2021, the US FDA issued a new checklist, labeling, and rupture-screening recommendations for breast implants to improve the decision-making process.
Objectives
The aim of this study was to understand plastic surgeons' perspective on these changes and their perceived impact on clinical practice.
Methods
In September 2023, a 27-question multiple-choice cross-sectional survey was distributed to 4352 active members of the American Society of Plastic Surgeons to evaluate attitudes on the FDA's black-box warning, informed decision checklist, and updated rupture-screening recommendations.
Results
A total of 591 responses were collected (13.6%). The majority of respondents were between the ages of 45 and 64 years (58%) and had been in practice for more than 20 years (52%). Surgeons felt that some additions were appropriate; however, the majority (57%) stated that the informed decision checklist did not have a positive impact on workflow; 66% were also neutral or disagreed with the reported incidence rates related to complications and cancer. Nearly half of respondents (47%) did not feel the black-box warning improved their patients’ understanding of the risks and benefits. Additionally, 47% of respondents also believed these requirements, in combination, did not improve the overall patient experience with implants.
Conclusions
Respondents had an overall positive response towards the addition of risk information provided by the FDA-issued guidance and updates to rupture-screening recommendations. However, they remained divided as to whether the black-box warning and patient decision checklist had an overall positive impact on clinical practice patterns. Level of Evidence: 4
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Zitieren
APA
Villanueva, K., Gupta, N., Alnaseri, T., Da Lio, A. L., Roostaeian, J., & DeLong, M. (2024). Plastic Surgeons’ Perspective on the FDA Breast Implant Regulatory Mandates. Aesthetic Surgery Journal. https://doi.org/10.1093/asj/sjae106
Vancouver
Villanueva K, Gupta N, Alnaseri T, Da Lio AL, Roostaeian J, DeLong M. Plastic Surgeons’ Perspective on the FDA Breast Implant Regulatory Mandates. Aesthetic Surgery Journal. 2024. doi:10.1093/asj/sjae106
BibTeX
@article{Villanueva2024,
author = {Villanueva, Karie and Gupta, Nisha and Alnaseri, Tahera and Da Lio, Andrew L and Roostaeian, Jason and DeLong, Michael},
title = {Plastic Surgeons’ Perspective on the FDA Breast Implant Regulatory Mandates},
journal = {Aesthetic Surgery Journal},
year = {2024},
doi = {10.1093/asj/sjae106}
}
EUVIMED